Principal Investigators: Jef Boeke, PhD
Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The company has assembled a toolkit of disruptive platform technologies–including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform–to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realizing its full potential. The company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms. For example, Replay’s synHSV™ technology, a high-payload-capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs, and industry experts.